Pfizer CEO, Albert Bourla, predicts a consumer market for obesity drugs similar to the success of Viagra. The company did not anticipate the rapid growth of cash-pay market for obesity drugs after acquiring Metsera. Pfizer plans to launch 10 phase 3 studies of obesity compounds and expects bumpy revenue growth until 2029.

Pfizer invested in obesity treatments after acquiring Metsera for $10 billion. The company aims to develop new blockbuster drugs and expand its expertise in commercial, development, and discovery. Pfizer also signed a deal with the Trump administration to lower drug prices in Medicaid in exchange for tariff relief.

Bourla believes government deals will pressure European countries to increase drug prices. If forced to lower prices in the U.S., companies may stop supplying drugs to countries offering lower prices. This could lead to a shortage of new medicines in those countries. Pfizer is focused on navigating challenges to maintain revenue growth.

Read more at Yahoo Finance: Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra